BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36597230)

  • 21. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
    Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
    Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
    Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
    Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix.
    Merat S; Blümlein T; Klarhöfer M; Nickel D; Singer G; Zöllner FG; Schoenberg SO; Kubik-Huch RA; Hausmann D; Hefermehl L
    Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33808402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
    Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
    AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-gantry MRI guided prostate biopsy diagnosis of prostatitis and its relationship with PIRADS V.2 based score.
    Jyoti R; Jina NH; Haxhimolla HZ
    J Med Imaging Radiat Oncol; 2017 Apr; 61(2):212-215. PubMed ID: 27987276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative multiparametric magnetic resonance imaging for prostate cancer: further outcome and consequences.
    Haack M; Miksch V; Tian Z; Duwe G; Thomas A; Borkowetz A; Stroh K; Thomas C; Haferkamp A; Höfner T; Boehm K
    World J Urol; 2022 Dec; 40(12):2947-2954. PubMed ID: 36318314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using whole-mount histology as the standard of reference.
    Girometti R; Giannarini G; Greco F; Isola M; Cereser L; Como G; Sioletic S; Pizzolitto S; Crestani A; Ficarra V; Zuiani C
    J Magn Reson Imaging; 2019 Feb; 49(2):546-555. PubMed ID: 30187600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Differentiation of prostatitis and clinically significant prostate cancer in peripheral zone using the prostate imaging-reporting and data system].
    Zhang TH; Hu CH; Chen JX; Xu ZD; Hu YJ; Cai HF; Shen LP
    Zhonghua Yi Xue Za Zhi; 2019 Aug; 99(31):2455-2458. PubMed ID: 31434427
    [No Abstract]   [Full Text] [Related]  

  • 32. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
    Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
    Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: Our experience in 950 cases.
    Pepe P; Candiano G; Pepe L; Pennisi M; Fraggetta F
    Arch Ital Urol Androl; 2021 Jun; 93(2):139-142. PubMed ID: 34286544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?
    Luzzago S; Petralia G; Musi G; Catellani M; Alessi S; Di Trapani E; Mistretta FA; Serino A; Conti A; Pricolo P; Nazzani S; Mirone V; Matei DV; Montanari E; de Cobelli O
    Clin Genitourin Cancer; 2019 Apr; 17(2):88-96. PubMed ID: 30527286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.
    Israël B; Leest MV; Sedelaar M; Padhani AR; Zámecnik P; Barentsz JO
    Eur Urol; 2020 Apr; 77(4):469-480. PubMed ID: 31767492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
    Huebner NA; Korn S; Resch I; Grubmüller B; Gross T; Gale R; Kramer G; Poetsch N; Clauser P; Haitel A; Fajkovic H; Shariat SF; Baltzer PA
    Eur Radiol; 2021 Jun; 31(6):3754-3764. PubMed ID: 33263793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis.
    Junker D; Quentin M; Nagele U; Edlinger M; Richenberg J; Schaefer G; Ladurner M; Jaschke W; Horninger W; Aigner F
    World J Urol; 2015 Jul; 33(7):1023-30. PubMed ID: 25081011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy and Variability of Prostate Multiparametric Magnetic Resonance Imaging Interpretation Using the Prostate Imaging Reporting and Data System: A Blinded Comparison of Radiologists.
    Pickersgill NA; Vetter JM; Andriole GL; Shetty AS; Fowler KJ; Mintz AJ; Siegel CL; Kim EH
    Eur Urol Focus; 2020 Mar; 6(2):267-272. PubMed ID: 30327280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
    Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
    Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.